Topics › Health Sciences › Medicine › Oncology
HER2/EGFR in Cancer Research Sign in to save
25
Aachen papers (primary topic)
104
Further papers (secondary topic)
393
Citations
39
Aachen authors
Papers per year
20
21
22
23
24
25
26
Papers 25
Open in paper search →-
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Ulrike Anneliese Nitz, Oleg Gluz, Monika Graeser, Matthias Christgen, Sherko Küemmel, Eva‐Maria Grischke, +43 more
93citations -
Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM12020 Journal of Pharmacokinetics and Pharmacodynamics article Medicine HER2/EGFR in Cancer Research Open access
Alison M. Betts, Tracey H. Clark, Paul Jasper, John E. Tolsma, Piet H. van der Graaf, Edmund I. Graziani, +4 more
25citations -
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
Evandro de Azambuja, M. Piccart-Gebhart, Shona Fielding, John Townend, D.W. Hillman, M. Colleoni, +36 more
11citations -
HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice2024 International Journal of Molecular Sciences article Medicine HER2/EGFR in Cancer Research Open access
Veruschka Albert, Christina Bruß, Deniz Tümen, Gerhard Piendl, Florian Weber, Edgar Dahl, +4 more
7citations -
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study
Mattea Reinisch, Michael Untch, Rolf Mahlberg, Toralf Reimer, T Hitschold, Frederik Marmé, +18 more
5citations -
Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial.
Paolo Giovanni Nuciforo, John Townend, Cristina Saura, E. de Azumbaja, Florentine Hilbers, Anna Manukyants, +13 more
3citations
Most active Aachen authors
-
Judith R. Kroep 14,032 citations overall5 papers
-
Elmar Stickeler 12,242 citations overall4 papers
-
Jelle Wesseling 21,738 citations overall3 papers
-
Katja Krauss 743 citations overall3 papers
-
Cornelis J.�H. van de Velde 79,446 citations overall1 paper
-
Tjalling Bosse 25,826 citations overall1 paper
-
Huib Ovaa 23,982 citations overall1 paper
-
Vincent T.H.B.M. Smit 21,679 citations overall1 paper
-
Lothar Rink 20,589 citations overall1 paper
-
FERRY A. OSSENDORP 18,702 citations overall1 paper
-
Gerrit‐Jan Liefers 13,081 citations overall1 paper
-
Thorbald van Hall 12,094 citations overall1 paper
-
Edgar Dahl 11,346 citations overall1 paper
-
J. Sjef Verbeek 10,992 citations overall1 paper
-
Nanda Horeweg 9,650 citations overall1 paper